相关实验视频
Updated: Jun 12, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
向USP47通过破坏PD-L1的稳定性来增强肝细胞癌的免疫疗法
Yixiao Jiang1, Ze Yu2, Jie Wang3
1Department of General Surgery, Zhoushan Hospital, Wenzhou Medical University, Zhoushan, Zhejiang, China; Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
在肝细胞癌 (HCC) 中,USP47使PD-L1蛋白分离并稳定. 与P5091一起抑制USP47增强了抗PD-1疗法的疗效,改善了HCC治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 针对PD-1/PD-L1相互作用的肝细胞癌 (HCC) 免疫疗法在许多患者中显示出有限的疗效.
- 了解控制PD-L1表达的机制对于改善免疫治疗反应率至关重要.
研究的目的:
- 研究USP47在调节PD-L1蛋白表达中的作用及其对HCC进展的影响.
- 评估针对USP47的治疗潜力,与PD-1阻断结合用于HCC治疗.
主要方法:
- 通过数据库选 (TCGA,GEO) 确定了USP47.
- 评估了蛋白质水平,相互作用和细胞功能 (增殖,迁移,入侵).
- 与抗PD-1治疗的USP47抑制剂 (P5091) 的体内疗效在HCC小鼠模型中进行了评估.
主要成果:
- USP47在HCC上升调节,与预后不佳相关.
- USP47 缺陷通过降低 PD-L1 蛋白质稳定性 (deubiquitination) 来降低 HCC 细胞的增殖,迁移,入侵和免疫逃避.
- 与抗PD-1疗法相结合的USP47抑制 (P5091) 在HCC模型中显著改善了治疗结果.
结论:
- 通过稳定PD-L1.1,USP47在HCC细胞增殖,入侵和免疫逃避中发挥着关键作用.
- 针对USP47增强了PD-1封锁的有效性,为HCC提供了一个有前途的治疗策略.
- USP47作为一种新的预后生物标志物和肝细胞癌的治疗点.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation